Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer-Reference-Cited by-同舟云学术

Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer

Published:2015-01 Issue:1 Volume:67 Page:53-60
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Efstathiou Eleni,Titus Mark,Wen Sijin,Hoang Anh,Karlou Maria,Ashe Robynne,Tu Shi Ming,Aparicio Ana,Troncoso Patricia,Mohler James,Logothetis Christopher J.

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Abiraterone and increased survival in metastatic prostate cancer;De Bono;N Engl J Med,2011

2. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study;Scher;Lancet,2010

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

5. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone;Efstathiou;J Clin Oncol,2012

Cited by 210 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small-Molecule Approaches to Target Transcription Factors;Annual Review of Cancer Biology;2024-06-12

2. Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial;Prostate Cancer and Prostatic Diseases;2024-05-07

3. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67;The Prostate;2024-04-17

4. Molecular heterogeneity in prostate cancer and the role of targeted therapy;Life Sciences;2024-01

5. Androgen receptor-dependent mechanisms mediating therapy resistance in prostate cancer;Therapy Resistance in Prostate Cancer;2024